L. Chitia

Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial.

S. Tjulandin, A. Tryakin, M. Fedyanin, 2019, Journal of Clinical Oncology.